Ariad Pharmaceuticals Inc
ARIA
ARIA was delisted on the 15th of February, 2017.
200 hedge funds and large institutions have $2.13B invested in Ariad Pharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 66 increasing their positions, 73 reducing their positions, and 32 closing their positions.
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
1% less funds holding
Funds holding: 202 → 200 (-2)
10% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 73
7% less capital invested
Capital invested by funds: $2.28B → $2.13B (-$155M)
44% less call options, than puts
Call options by funds: $20.8M | Put options by funds: $37.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.2M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$20.5M |
| 3 |
Jennison Associates
New York
|
+$20M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$18.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$61.9M |
| 2 |
Goldman Sachs
New York
|
-$23.7M |
| 3 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
-$13.9M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$12.6M |
| 5 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$12M |
ARIA Hedge Fund Activity: Q4 2016 in Review
200 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2016, worth a combined $2.13B — down 6.8% from $2.28B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ARIA positions and 32 closed out — a net gain of 1 holder — while 66 added to existing stakes and 73 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $35.2M. The largest seller was Consonance Capital Management, cutting an estimated $61.9M.
- 200 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2016, down from 202 in Q3 2016.
- Funds reported $2.13B of Ariad Pharmaceuticals Inc stock for Q4 2016, down 6.8% quarter-over-quarter.
- 33 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2016 and 32 closed out, a net change of +1 holder.
- The largest Ariad Pharmaceuticals Inc buyer in Q4 2016 was Fidelity Investments, an estimated $35.2M added.
- The largest Ariad Pharmaceuticals Inc seller in Q4 2016 was Consonance Capital Management, an estimated $61.9M sold.
Based on aggregated 13F filings for Q4 2016.